Skip to main content
    S

    Sonnet Biotherapeutics Holdings Inc (SONN)

    Official site

    BIOTECHNOLOGY

    $1.26
    -1.84 (-59.35%)

    Last updated: Dec 02, 2025 at 4:00 PM ET

    Sonnet Biotherapeutics Holdings Inc (SONN) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2025. Financial statements from company filings, amounts in US dollars.

    Sonnet Biotherapeutics Holdings reported revenue of $1.00M for the fiscal year ended Sep 30, 2025, up 5268.8% from the year before. That year, net income was -$16.11M with a net margin of -1611.3%, operating cash flow was -$12.83M and free cash flow was -$12.83M. The quarter ended Jun 30, 2025 had revenue of $0 and net income of -$3.78M.

    Revenue and Margins

    Over the 9 years to Sep 2025, revenue fell from $41.70M, a compound annual decline of 33.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$1.00M+5268.8%N/A-1584.4%-1611.3%
    Sep 2024$18.63K-87.4%100.0%-63617.9%-39929.3%
    Sep 2023$147.81K-57.8%100.0%-12714.5%-12741.6%
    Sep 2022$349.94K-27.6%-6027.9%-8478.3%-8508.3%
    Sep 2021$483.63KN/A100.0%-5187.4%-5170.5%
    Sep 2020$0N/AN/AN/AN/A
    Dec 2019$40.61MN/A80.5%-11.6%-12.4%
    Sep 2019$40.61MN/A80.5%-11.6%-12.0%
    Sep 2017$41.43M-0.6%4.9%-6.1%-16.4%
    Sep 2016$41.70MN/A8.0%-6.3%-21.8%
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Dec 2019Sep 2019Sep 2017Sep 2016
    Revenue$1.00M$18.63K$147.81K$349.94K$483.63K$0$40.61M$40.61M$41.43M$41.70M
    Cost of revenueN/A$83.11K$75.75K$93.26K$95.16K$58.31K$7.93M$7.93M$39.41M$38.38M
    Gross profitN/A$18.63K$147.81K-$21.09M$483.63K-$58.31K$32.68M$32.68M$2.03M$3.33M
    Research and development$8.36M$5.74M$11.81M$21.44M$16.63M$9.88M$2.20M$2.20M$0$0
    Operating income-$15.84M-$11.85M-$18.79M-$29.67M-$25.09M-$17.41M-$4.71M-$4.71M-$2.52M-$2.62M
    Net income-$16.11M-$7.44M-$18.83M-$29.77M-$25.01M-$24.27M-$5.03M-$4.87M-$6.79M-$9.08M
    EBITDA-$15.84M-$11.77M-$18.72M-$29.58M-$24.99MN/A-$2.54MN/AN/A$541.15K
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Revenue$0$0$1.00M$104.39K$0$0$18.63K$37.26K$36.85K$36.45K$37.26K$62.75K
    Gross profit-$22.16K-$22.09K-$886.08K-$21.61K-$21.04K-$20.50K-$1.35K$17.79K$17.87K$17.57K$18.82K$44.83K
    Operating income-$3.81M-$4.23M-$2.85M-$3.17M-$3.53M-$3.87M-$1.28M-$3.60M-$3.92M-$5.66M-$5.61M-$7.38M
    Net income-$3.78M-$3.49M-$3.16M-$3.13M-$3.51M$365.43K-$1.17M-$3.68M-$3.95M-$5.67M-$5.54M-$7.49M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded short-term debt of $46.57K by $5.07M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Dec 2018Sep 2018Sep 2017
    Total assets$14.88M$2.77M$5.43M$5.83M$28.99M$7.99M$39.75K$29.79MN/A$30.18M
    Current assets$14.34M$2.12M$4.74M$5.41M$28.81M$7.64M$39.75K$1.34MN/A$1.80M
    Cash and equivalents$5.12M$149.46K$2.27M$3.05M$27.62M$7.35M$35.65K$524.11KN/A$438.49K
    Total liabilities$4.10M$3.26M$5.66M$8.37M$6.73M$4.97M$2.89M$21.54MN/A$18.69M
    Short-term debt$46.57K$84.29K$146.10K$52.08K$95.27K$103.24K$217.38KN/AN/A$8.74M
    Long-term debtN/AN/AN/AN/AN/A$124.88K$709.70K$3.00MN/A$212.26K
    Shareholder equity$10.79M-$485.74K-$225.98K-$2.54M$22.26M$3.02M-$2.85M$7.43MN/A$10.71M
    Fiscal years ended Sep 2017 to Sep 2025

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$14.88M$2.06M$3.84M$7.18M$2.77M$5.80M$5.91M$5.34M$5.43M$10.03M$13.31M$4.94M
    Total liabilities$4.10M$5.10M$3.17M$3.15M$3.26M$3.18M$2.86M$2.77M$5.66M$6.62M$7.94M$8.48M
    Cash and equivalents$5.12M$321.30K$2.06M$4.86M$149.46K$3.55M$3.79M$3.02M$2.27M$7.02M$11.39M$1.70M
    Shareholder equity$10.79M-$3.05M$662.26K$4.04M-$485.74K$2.62M$3.05M$2.57M-$225.98K$3.42M$5.37M-$3.54M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Dec 2019Sep 2019Sep 2018Sep 2017
    Operating cash flow-$12.83M-$8.61M-$21.34M-$27.69M-$22.55M-$15.61M-$2.23M-$2.23M-$672.06K-$724.43K
    Capital expenditures$0$3$443.25K$896.48K$3.62K$76.18K$2.39M$2.39M$0$1.63M
    Free cash flow-$12.83M-$8.61M-$21.79M-$28.58M-$22.56M-$15.69M-$4.62M-$4.62M-$672.06K-$2.35M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$142.22KN/AN/A
    Investing cash flow-$12.00K-$12.00K-$443.25K-$896.48K-$3.62K-$76.18K$678.67K-$2.44M$118.01K-$439.30K
    Financing cash flow$26.05M$6.49M$21.01M$4.01M$42.83M$23.01M$2.26M$2.26MN/A$1.36M
    Fiscal years ended Sep 2017 to Sep 2025

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$1.76M-$2.47M-$2.91M-$3.17M-$3.07M$723.79K-$3.09M-$4.56M-$6.17M-$4.70M-$5.92M
    Capital expenditures$0$0$0$0$12.00K$0$3$170.00K$12.00K$261.25K$0
    Free cash flow-$1.76M-$2.47M-$2.91M-$3.17M-$3.08M$723.79K-$3.09M-$4.73M-$6.18M-$4.96M-$5.92M
    Last 11 quarters

    Frequently Asked Questions About SONN

    What is Sonnet Biotherapeutics Holdings' annual revenue?

    Sonnet Biotherapeutics Holdings reported revenue of $1.00M for the fiscal year ended Sep 30, 2025.

    How fast is Sonnet Biotherapeutics Holdings' revenue growing?

    Revenue was up 5268.8% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 41.9%.

    Is Sonnet Biotherapeutics Holdings profitable?

    No. Sonnet Biotherapeutics Holdings reported net income of -$16.11M for the fiscal year ended Sep 30, 2025, with a net margin of -1611.3%.

    How much free cash flow does SONN generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$12.83M minus capital expenditures of $0 produced free cash flow of -$12.83M.

    How much debt does Sonnet Biotherapeutics Holdings have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $46.57K and cash and equivalents of $5.12M.